Agilent Introduces MAM Solution to Streamline Biopharma Quality Control
Event summary
- Agilent launched a Multi-Attribute Method (MAM) workflow for biopharma quality control on May 26, 2026.
- The solution integrates software, instrumentation, and consumables to facilitate LC/HRMS in regulated testing environments.
- Designed to support late-stage development and commercial manufacturing, the workflow aims to reduce complexity and training requirements.
- The solution is available globally and supports pharmaceutical and biopharmaceutical manufacturers seeking to adopt LC/HRMS-based methods.
The big picture
Agilent’s MAM solution addresses the growing complexity of biologic products, which require advanced analytical techniques for quality control. As biologics become more sophisticated, the demand for consolidated, efficient testing methods like MAM is rising. This launch positions Agilent to capitalize on regulatory and industry shifts toward more stringent analytical control in biopharma manufacturing.
What we're watching
- Regulatory Adoption
- How the alignment with USP chapter <1060> will influence broader regulatory acceptance of MAM in QC environments.
- Market Penetration
- The pace at which biopharma manufacturers adopt Agilent’s MAM solution for complex biologics like gene therapies and antibody-drug conjugates.
- Competitive Dynamics
- Whether Agilent can maintain a leadership position as competitors develop similar MAM solutions for biopharma QC.
Related topics